Month: March 2023

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national...

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

Marcin Szumowski Chief Executive Officer Samson Fung Chief Medical Officer OATD-02 First-in-class dual arginase inhibitorMolecure announces first patient dosed in...

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products...

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2022 Financial Results and Host a Conference Call on Tuesday, March 14, 2023

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company,...

error: Content is protected !!